Aclaris Therapeutics (ACRS) CFO logs RSU vesting, tax share withholding in Form 4

Rhea-AI Filing Summary

Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported routine equity compensation activity involving restricted stock units and common stock. On February 1, 2026, 14,750 restricted stock units were converted into an equal number of shares of Aclaris common stock, reflecting previously granted equity awards.

To cover related tax withholding on this vesting, the issuer withheld 4,984 shares of common stock at $3.51 per share. Following these transactions, Balthaser directly held 170,179 shares of common stock and 29,500 restricted stock units. The remaining restricted stock units vest in four equal annual installments beginning on the first anniversary of February 1, 2024, contingent on his continued service.

Insider Trade Summary

14,750 shares exercised/converted

Mixed 3 txns

Insider Balthaser Kevin

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	14,750	$0.00	--
Exercise	Common Stock	14,750	$0.00	--
Tax Withholding	Common Stock	4,984	$3.51	$17K

Holdings After Transaction: Restricted Stock Units — 29,500 shares (Direct); Common Stock — 175,163 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Balthaser Kevin

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/01/2026		M		14,750	A	(1)	175,163	D
Common Stock	02/01/2026		F(2)		4,984	D	$3.51	170,179	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/01/2026		M			14,750	(3)	(3)	Common Stock	14,750	$0	29,500	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

2. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

3. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

	/s/ Matthew Rothman, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Aclaris Therapeutics (ACRS) report for CFO Kevin Balthaser?

Aclaris Therapeutics reported routine equity compensation activity for CFO Kevin Balthaser. On February 1, 2026, 14,750 restricted stock units converted into the same number of common shares, and shares were withheld solely to satisfy tax obligations tied to this vesting event.

How many Aclaris Therapeutics (ACRS) shares did the CFO receive and retain in this Form 4?

The CFO had 14,750 restricted stock units convert into common shares. Of these, 4,984 shares were withheld by the issuer to cover taxes at $3.51 per share, leaving him with a direct holding of 170,179 Aclaris common shares after the transactions.

What do the restricted stock units (RSUs) in the Aclaris Therapeutics (ACRS) Form 4 represent?

Each restricted stock unit represents a right to receive one Aclaris common share. After the reported vesting, the CFO held 29,500 RSUs, which are scheduled to vest in four equal annual installments starting on the first anniversary of February 1, 2024, subject to continued service.

Why were shares withheld in the Aclaris Therapeutics (ACRS) CFO Form 4 filing?

The issuer withheld shares to satisfy the CFO’s tax withholding obligations. Specifically, 4,984 common shares were withheld at $3.51 per share in connection with the vesting and settlement of restricted stock units, rather than being sold in an open-market transaction.

How many Aclaris Therapeutics (ACRS) shares and RSUs does the CFO hold after this Form 4?

After the reported transactions, the CFO directly held 170,179 common shares. He also beneficially owned 29,500 restricted stock units, which are scheduled to vest in four equal installments over four years beginning on the first anniversary of February 1, 2024.